<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150540</url>
  </required_header>
  <id_info>
    <org_study_id>SPD405-309</org_study_id>
    <nct_id>NCT00150540</nct_id>
  </id_info>
  <brief_title>A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.</brief_title>
  <official_title>A Long Term, Open Label Extension Study of Protocols LAM-IV-301, LAM-IV 303, LAM-IV 307 AND LAM-IV 308.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of lanthanum carbonate in patients&#xD;
      undergoing dialysis who have received lanthanum carbonate in the previous studies and wish to&#xD;
      continue treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2002</start_date>
  <completion_date type="Actual">June 29, 2005</completion_date>
  <primary_completion_date type="Actual">June 29, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in pre-dialysis serum phosphate levels</measure>
    <time_frame>Baseline, Months 3, 6, 9, 12, 15, 18, 21, 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of pre-dialysis serum phosphate levels</measure>
    <time_frame>Baseline, Months 3, 6, 9, 12, 15, 18, 21, 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma lanthanum levels</measure>
    <time_frame>Baseline, Months 3, 6, 9, 12, 15, 18, 21, 24.</time_frame>
  </secondary_outcome>
  <enrollment>93</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum carbonate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who participated in LAM-IV-301, LAM-IV-303, LAM-IV-307 OR LAM-IV-308 and&#xD;
             received lanthanum carbonate&#xD;
&#xD;
          -  Patients must continue to require treatment with a phosphate binder for&#xD;
             hyperphosphatemia&#xD;
&#xD;
          -  male or non-pregnant female who agrees to use an effective contraceptive method while&#xD;
             on study treatment and for 30 days thereafter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients withdrawn from LAM-IV-301, LAM-IV-303 OR LAM-IV-307 prior to randomization&#xD;
&#xD;
          -  Patients withdrawn from LAM-IV-301, LAM-IV-303, LAM-IV-307 OR LAM-IV-308 due to&#xD;
             adverse events termed &quot;possible&quot; or &quot;related&quot; to study medication&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

